Skip to main content
ホーム / ニュース / Certara Acquires UK-based Insight Medical Writing

Certara Acquires UK-based Insight Medical Writing

Expands global reach and deepens regulatory expertise

PRINCETON, NJ.— 2021 年 6 月 10 日– Certara, Inc., the global leader in biosimulation, today announced the acquisition of Insight Medical Writing, based in Oxford in the United Kingdom.  Financial terms of the transaction were not disclosed.

Founded in 2002, Insight Medical Writing offers regulatory services and medical writing. Its medical writers are all PhD trained and come from diverse backgrounds such as molecular biology, oncology, and pharmacology. The acquisition expands Certara’s regulatory science capabilities in the UK and Europe.

“We are pleased to welcome Insight Medical Writing to Certara,” said Justin Edge, president of Certara’s Regulatory and Access Division. “Insight Medical enhances our ability to support the regulatory submissions of our growing client base in the United Kingdom and Europe. Together with our new colleagues, we look forward to expanding our regulatory science capabilities and global footprint while providing Synchrogenix’s advanced regulatory technology to more clients.”

The global regulatory landscape is complex and evolving.  Biopharmaceutical sponsors need to rely on partners that can support sequential, parallel, or even simultaneous submissions to multiple global regulatory agencies. Certara accelerates these steps in the drug development process through its regulatory talent and technology.

“Joining Certara is a natural next step in our journey. We share common values and a commitment to quality,” said Kerry Walker, founder of Insight Medical Writing.  “This is a complementary fit in terms of culture, clients and technology. We are excited about joining the Certara family and the opportunities it will bring, in particular allowing us to expand our services to our clients.”

For more information on Certara’s regulatory science solutions, please visit

Certara(サターラ) について

Certara accelerates medicines using biosimulation software and technology to transform traditional drug discovery and development. バイオ医薬品企業1,650社以上、主要学術機関、主要な規制当局がサターラのソフトウェアやコンサルティングサービスを利用しております。弊社のお客様は61か国以上に広がっております。


Jieun W. Choe


赤津 笑美

Powered by GlobalLink OneLink Software